AstraZeneca PLC LS-Medium-Term Notes 2007(31)
- BID
104.41
- ASK
104.68
- 100,000 Nom.100,000 Nom.
- 07/28, 16:15:51 PM
Type of financial instrument
Corporate Bond
Sub-Type
Health Care
Yield
4.80
Yield spread Bundesanleihe
1.8999
Tradable for private investors
Yes
Minimum amount tradeable unit
50,000.00
Maturity
13/11/2031
Interest Rate
5.75 %
Currency
British Pound Sterling
Facts & figures
Price data
| TRADE PLATFORM | ||
| LAST PRICE / YIELD | 104.38 G / 4.80 | 0 Units |
| PRICE DETERMINATION TIME | 07/28/2026 / 04:04:10 PM | |
| DAILY VOLUME (NOMINAL) | 0 | |
| YIELD SPREAD | 1.8999 | |
| FIXINGPRICE | - | |
| DAILY HIGH / LOW | 104.45 | 104.13 |
| PREV. DAY'S PRICE | 104.239 | (07/27) |
| CHANGE DAY BEFORE | +0.14 | 0.14 % |
| 52 WEEK HIGH / LOW | 108.23 (01/15) | 102.55 (03/23) |
Master Data
| WKN | A0TL97 |
| ISIN | XS0330497149 |
| SYMBOL | - |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Corporate Bond |
| SUB-TYPE | Health Care |
| ISSUER | AstraZeneca PLC |
| S&P RATING | Please log in to view this field |
| (TRADING) SEGMENT / TICKS | -/ - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| INTEREST RATE | 5.75 % |
| INTEREST RUN FROM | 13/11/2007 |
| NEXT INTEREST PAYMENT | 13/11/2026 |
| UNIT INTEREST FROM NOMINAL AMMOUNT | 4.08 % |
| TRADING CURRENCY / NOTATION | British Pound Sterling/ Percent |
| NOMINAL CURRENCY | British Pound Sterling |
| SETTLEMENT CURRENCY | Euro |
| QUOTATION | Continuous trading |
| ISSUING VOLUME | 350.00 Mil. |
| MINIMUM AMOUNT TRADEABLE UNIT | 50,000.00 |
| SMALLEST TRADEABLE UNIT | 1,000.00 |
| MATURITY | 13/11/2031 |
| MARKET MAKER | - |
| STEP UP/ DOWN WHEN RATING CHANGES | No |
| STEP UP FIXED AT ISSUE | No |
| STEP DOWN FIXED AT ISSUE | No |
| BOND CALLABLE BY THE ISSUER | No |
| BOND IS SUBORDINATED | No |
Description
Local currency bond: GBP.
Tradability Information
Please log in to see the tradability information for this stock.Not registered yet? Create your free account here.
Company profile
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.